News | Stents Bifurcation | September 21, 2017

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award

Stent is first dedicated bifurcation device to receive U.S. regulatory approval

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award

September 21, 2017 — Cardinal Health and Tryton Medical Inc. announced that the Tryton coronary Side Branch Stent was recognized by healthcare improvement company Premier Inc. with the Technology Breakthrough Award. Premier’s Technology Breakthrough Award is granted to cutting-edge products that significantly advance healthcare in terms of safety, clinical outcomes and/or operational efficiency.

The Tryton Side Branch Stent, the first dedicated bifurcation device to receive regulatory approval in the United States, is approved for the treatment of de novo coronary bifurcation lesions involving large side branches (appropriate for a ≥2.5mm stent). Cordis, Cardinal Health’s interventional vascular business, is the exclusive U.S. distributor of the Tryton Side Branch Stent. 

The Tryton Side Branch Stent System is built using Tri-Zone technology for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

For more information: www.trytonmedical.com


Related Content

News | Stents Bifurcation

September 21, 2022 — Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the ...

Home September 21, 2022
Home
News | Stents Bifurcation

May 29, 2018 – Medtronic plc announced the initiation of a U.S. clinical study to assess the safety and efficacy of drug ...

Home May 29, 2018
Home
News | Stents Bifurcation

January 18, 2018 – West Hills Hospital & Medical Center, a full-service acute care facility, announces the first ...

Home January 18, 2018
Home
Videos | Stents Bifurcation

Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at ...

Home November 15, 2017
Home
News | Stents Bifurcation

November 1, 2017 — The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion ...

Home November 01, 2017
Home
News | Stents Bifurcation

March 31, 2017 — Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch ...

Home March 31, 2017
Home
Videos | Stents Bifurcation

This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent. It became the first ...

Home March 06, 2017
Home
Technology | Stents Bifurcation

March 6, 2017 – The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) for the Tryton Side ...

Home March 06, 2017
Home
News | Stents Bifurcation

October 28, 2016 – Tryton Medical Inc., a primary developer of stents to treat coronary bifurcation lesions, and ...

Home October 28, 2016
Home
News | Stents Bifurcation

October 14, 2015 — Tryton Medical Inc. announced results from the pivotal Tryton Confirmatory Study confirming the ...

Home October 14, 2015
Home
Subscribe Now